Ocular Therapeutix, INC Form 4 insider transactions

Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix, Inc., sold 3,061 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Peter Kaiser, Chief Development Officer of Ocular Therapeutix, sold 3,009 shares of common stock to cover tax obligations related to vesting restricted stock units.

Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix, sold 1,895 shares of common stock to cover tax obligations related to vesting restricted stock units.

Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, receives restricted stock units (RSUs) and performance stock units (PSUs) under the company's 2021 Stock Incentive Plan.

Nadia Waheed, Chief Medical Officer of Ocular Therapeutix, reports the acquisition of restricted stock units and stock options.

Donald Notman, CFO and COO of Ocular Therapeutix, was granted stock options and restricted stock units (RSUs) on February 11, 2025.

Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix, was granted stock options and restricted stock units (RSUs) on February 11, 2025, according to a Form 4 filing.

Donald Notman, CFO and COO of Ocular Therapeutix, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Ocular Therapeutix's Chief Scientific Officer, Jeffrey S. Heier, sold 2,948 shares of common stock to cover tax obligations related to vesting restricted stock units.

Ocular Therapeutix's Chief Development Officer, Peter Kaiser, sold 2,897 shares of common stock to cover tax obligations related to vesting restricted stock units.

Ocular Therapeutix's Chief Strategy Officer, Sanjay Nayak, sold 1,814 shares of common stock to cover tax obligations related to vesting restricted stock units.

Ocular Therapeutix's Executive Chairman, President, and CEO, Pravin Dugel, sold 20,680 shares of common stock to cover tax obligations related to vesting restricted stock units.

Todd Anderman, Chief Legal Officer of Ocular Therapeutix, Inc., was granted stock options and restricted stock units (RSUs) on October 7, 2024.

Peter Kaiser, Chief Development Officer of Ocular Therapeutix, was granted 100,000 restricted stock units and options to purchase 200,000 shares of common stock.

Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix, Inc., was granted restricted stock units and stock options on October 2, 2024.

Donald Notman, Chief Operating Officer and Chief Financial Officer of Ocular Therapeutix, reports the acquisition of restricted stock units and stock options.

Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix, sold 1,832 shares of common stock to cover tax obligations related to vesting restricted stock units.

Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, sold 20,880 shares of common stock to cover tax obligations related to vesting restricted stock units.

Director Richard L. Lindstrom reports exercising stock options and receiving restricted stock units in Ocular Therapeutix, Inc.

Director Hong Seung Suh of Ocular Therapeutix, Inc. was granted stock options and restricted stock units (RSUs) on July 24, 2024.

Director Merilee Raines of Ocular Therapeutix, Inc. was granted 12,000 restricted stock units and options to purchase 36,000 shares of common stock on July 24, 2024.

Director Leslie J. Williams acquired 12,000 shares of common stock and options to purchase 36,000 shares of Ocular Therapeutix, Inc.

Director Charles M. Warden of Ocular Therapeutix, Inc. was granted 12,000 restricted stock units and options to purchase 36,000 shares of common stock on July 24, 2024.

Director Adrienne L. Graves received stock and option grants from Ocular Therapeutix, Inc. on July 24, 2024.

Nadia Waheed, Chief Medical Officer of Ocular Therapeutix, reports the acquisition of restricted stock units and stock options.

Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix, sold 2,274 shares of common stock to cover tax obligations related to vesting restricted stock units.

Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, sold shares to cover tax obligations related to vesting restricted stock units.

Summer Road LLC, a family office, purchased 930,851 shares of Ocular Therapeutix (OCUL) at $7.52 per share through a private placement.